NOVOCURE INC.
PORTSMOUTH, NH

Novocure Inc., a pioneering oncology company, originated from the innovative research of its founder, Professor Yoram Palti. Established in 2000 with operations first based out of his basement laboratory, Novocure has since grown into an international entity employing more than 450 people across the U.S., Europe, and Asia. The company is recognized for its development and marketing of Optune®, a Tumor Treating Fields (TTF) device designed to treat glioblastoma multiforme (GBM). This revolutionary therapy was first launched in the United States for recurrent GBM in 2011. Following FDA approval in October 2015, Novocure began selling Optune for adults with newly diagnosed GBM, in combination with temozolomide, marketed actively across the U.S., Germany, and Switzerland. Novocure started with a commitment to patient-first strategies that continue to inform its mission today. Over more than 15 years of research and key milestones, it has emerged as a leader in cancer treatment innovation. The company began with an ambition to leverage biophysics to create treatments that target tumor cells while minimizing damage to healthy tissue, thereby reducing the typically adverse effects associated with traditional cancer therapies. Holding its corporate headquarters at 1550 Liberty Ridge Drive, Suite 115, Wayne, PA, and registered as NOVOCURE (USA) INC., it filed under Florida corporation status in June 2009. The company's current official designation is F09000002102, with Broward County, FL noting its most recent event—an amendment on April 29, 2024—as part of its compliance documentation. Leadership at Novocure includes prominent roles held by Frank Leonard (President), Wilco Groenhuysen (President), and Ashley Cordova (CFO) among others. Interested parties can learn more about the company's initiatives through their official website, [novocure.com](http://www.novocure.com).